NMNAT2 | OmnibusX

Name	Number of supported studies	Average coverage
glutamatergic neuron	12 studies	64% ± 21%	Explore
GABAergic neuron	10 studies	64% ± 23%	Explore
oligodendrocyte precursor cell	10 studies	37% ± 19%	Explore
neuron	6 studies	46% ± 19%	Explore
interneuron	6 studies	72% ± 17%	Explore
retinal ganglion cell	6 studies	39% ± 8%	Explore
astrocyte	4 studies	44% ± 23%	Explore
granule cell	4 studies	61% ± 5%	Explore
endothelial cell	3 studies	67% ± 11%	Explore
GABAergic interneuron	3 studies	68% ± 1%	Explore
GABAergic amacrine cell	3 studies	32% ± 1%	Explore
glycinergic amacrine cell	3 studies	24% ± 3%	Explore
amacrine cell	3 studies	33% ± 8%	Explore

Name	Number of supported studies	Average coverage
brain	14 studies	46% ± 25%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
brain	93%	9334.23	2445 / 2642	95%	35.38	670 / 705
thymus	87%	1823.68	571 / 653	71%	9.72	428 / 605
adrenal gland	15%	187.59	38 / 258	73%	23.33	168 / 230
breast	66%	1322.78	304 / 459	19%	1.88	212 / 1118
adipose	75%	1044.89	900 / 1204	0%	0	0 / 0
ovary	1%	6.33	2 / 180	64%	6.73	274 / 430
pancreas	2%	15.51	6 / 328	62%	5.26	110 / 178
intestine	32%	302.67	307 / 966	21%	1.43	111 / 527
heart	49%	1634.99	421 / 861	0%	0	0 / 0
stomach	17%	182.34	62 / 359	26%	1.91	75 / 286
esophagus	6%	49.39	88 / 1445	31%	2.02	57 / 183
lung	1%	11.92	8 / 578	34%	5.04	393 / 1155
uterus	5%	52.34	8 / 170	29%	2.24	133 / 459
skin	24%	410.74	426 / 1809	7%	0.72	33 / 472
bladder	5%	42.14	1 / 21	20%	1.99	102 / 504
tonsil	0%	0	0 / 0	20%	0.99	9 / 45
prostate	1%	5.26	2 / 245	14%	0.80	72 / 502
kidney	0%	0	0 / 89	14%	1.53	126 / 901
blood vessel	11%	115.85	147 / 1335	0%	0	0 / 0
liver	0%	0	0 / 226	5%	0.35	21 / 406
lymph node	0%	0	0 / 0	3%	0.63	1 / 29
eye	0%	0	0 / 0	1%	0.09	1 / 80
muscle	0%	3.41	4 / 803	0%	0	0 / 0
peripheral blood	0%	1.67	2 / 929	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
spleen	0%	0	0 / 241	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

GO_0009435	Biological process	NAD biosynthetic process
GO_0061564	Biological process	axon development
GO_0009165	Biological process	nucleotide biosynthetic process
GO_2000766	Biological process	negative regulation of cytoplasmic translation
GO_0005802	Cellular component	trans-Golgi network
GO_0000139	Cellular component	Golgi membrane
GO_0030424	Cellular component	axon
GO_0005829	Cellular component	cytosol
GO_0045202	Cellular component	synapse
GO_0005770	Cellular component	late endosome
GO_0005794	Cellular component	Golgi apparatus
GO_0030659	Cellular component	cytoplasmic vesicle membrane
GO_0000309	Molecular function	nicotinamide-nucleotide adenylyltransferase activity
GO_0004515	Molecular function	nicotinate-nucleotide adenylyltransferase activity
GO_0140768	Molecular function	protein ADP-ribosyltransferase-substrate adaptor activity
GO_0005524	Molecular function	ATP binding

Gene name	NMNAT2
Protein name	Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2 (NMN/NaMN adenylyltransferase 2) (EC 2.7.7.1) (EC 2.7.7.18) (Nicotinamide mononucleotide adenylyltransferase 2) (NMN adenylyltransferase 2) (Nicotinate-nucleotide adenylyltransferase 2) (NaMN adenylyltransferase 2)
Synonyms	C1orf15 KIAA0479
Description	FUNCTION: Nicotinamide/nicotinate-nucleotide adenylyltransferase that acts as an axon maintenance factor (By similarity). Axon survival factor required for the maintenance of healthy axons: acts by delaying Wallerian axon degeneration, an evolutionarily conserved process that drives the loss of damaged axons (By similarity). Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP . Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate but with a lower efficiency . Cannot use triazofurin monophosphate (TrMP) as substrate . Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) . For the pyrophosphorolytic activity prefers NAD(+), NADH and NaAD as substrates and degrades nicotinic acid adenine dinucleotide phosphate (NHD) less effectively . Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) . Also acts as an activator of ADP-ribosylation by supporting the catalytic activity of PARP16 and promoting mono-ADP-ribosylation of ribosomes by PARP16 . .
Accessions	ENST00000294868.8 [Q9BZQ4-2] Q9BZQ4 ENST00000287713.7 [Q9BZQ4-1]

NMNAT2 report